Related Experiment Videos
The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic
D G Spiller1, R V Giles, C M Broughton
1Department of Haematology, University of Liverpool, UK.
Abstract:
During the course of a study aimed at improving antisense oligodeoxynucleotide-mediated ex vivo bone marrow purging of patients suffering from chronic myeloid leukemia (CML), the properties of a number of antisense structures intended to reduce the expression of c-myc, mutant p53, and bcr-abl mRNAs and proteins were examined. The majority of the antisense oligodeoxynucleotides were designed to be capable of directing ribonuclease H (RNase H) cleavage of their target mRNAs. Streptolysin O (SLO) reversible permeabilization was used to deliver the oligodeoxynucleotides into the CML line KYO-1. We found that the efficiency and specificity of antisense oligonucleotide-induced reductions of target protein expression depended on target protein half-life, the oligonucleotide structure, and the specific sequence within the target mRNA. Transient reductions of c-myc mRNA and protein were achieved with a chimeric methylphosphonate-phosphodiester oligodeoxynucleotide antisense to the initiation codon, but cell proliferation was unaffected. In contrast, a chimeric oligodeoxynucleotide of similar structure targeted to an alternative site in the coding region of c-myc mRNA reduced target mRNA and protein levels for over 24 hours and halted cell proliferation. Chimeric methylphosphonate-phosphodiester oligodeoxynucleotide antisense to a point mutation in KYO-1 p53 mRNA efficiently reduced target mRNA expression, but only small, transient reductions in p53 protein expression were observed. However, a chimeric methylphosphonate-phosphorothioate oligodeoxynucleotide targeted to the same site reduced p53 protein to 30% of control levels over a 48-hour period. BCR-ABL protein expression was unaffected by chimeric oligodeoxynucleotides targeted to the breakpoint in bcr-abl mRNA, even when mRNA levels at early times were substantially reduced.
Insights
Antisense oligodeoxynucleotides show promise for chronic myeloid leukemia (CML) treatment by reducing target gene expression. Optimized oligonucleotide structure and sequence are crucial for effective protein reduction and therapeutic outcomes.
Area of Science:
- Molecular Biology
- Cancer Research
- Oligonucleotide Therapeutics
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Ex vivo bone marrow purging aims to eliminate leukemia cells.
- Antisense oligodeoxynucleotides (ASOs) are investigated for targeted gene silencing.
Purpose of the Study:
- To improve antisense oligodeoxynucleotide (ASO)-mediated ex vivo bone marrow purging in CML.
- To examine the properties of ASOs targeting c-myc, mutant p53, and bcr-abl.
- To evaluate factors influencing ASO efficacy and specificity.
Main Methods:
- Design and synthesis of various antisense oligodeoxynucleotide structures.
- Utilizing ribonuclease H (RNase H) for mRNA cleavage.
- Employing Streptolysin O (SLO) for reversible cell permeabilization.
- Delivery of ASOs into CML cell line KYO-1.
Main Results:
- ASO efficacy depends on target protein half-life, ASO structure, and sequence.
- Chimeric ASOs targeting c-myc mRNA reduced protein levels and halted proliferation.
- Chimeric ASOs targeting mutant p53 mRNA showed variable protein reduction.
- BCR-ABL protein expression was not affected by ASOs targeting its mRNA breakpoint.
Conclusions:
- Optimized ASO design and sequence are critical for effective gene silencing in CML.
- ASO therapy shows potential for CML treatment, but target-specific optimization is necessary.
- Further research is needed to overcome challenges in BCR-ABL targeting.